1d
Zacks Investment Research on MSNSAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage StudyShares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...
SAVA releases top-line results from the ReThink ... the stock has plunged 80.9% compared with the industry’s 4.9% decline. Image Source: Zacks Investment Research Despite the setback, management ...
Please note: If days to cover is between 0 and 1, it is rounded up to 1 on Nasdaq.com. Source: Nasdaq Data Link; Subscribe for short interest feed for all Nasdaq listed securities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results